Clinical trials: ifosfamide
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma
Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma
This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma.
- Conditions
- Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma
- Trial name
- NCT00346164
- Testing
- doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery
- Where
- 187 sites in United States, Australia and 3 more
- Volunteers
- 588 people
- Sponsor
- Children's Oncology Group
Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors
This clinical trial is studying the side effects of combination chemotherapy and to see how well they work in treating patients with newly diagnosed localized Ewing sarcoma family of tumors.
- Trial name
- NCT00618813
- Testing
- radiation therapy, therapeutic conventional surgery, etoposide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Soft Tissue Sarcoma
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
The purpose of this study is to evaluate the safety of ifosfamide when added to the combination regimen of olaratumab and doxorubicin in participants with advanced or metastatic soft tissue sarcoma (STS).
- Trial name
- NCT03283696
- Testing
- Olaratumab, Doxorubicin, Ifosfamide
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Chemotherapy Induced Nausea and Vomiting
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)
This study will compare the safety and efficacy of a three-day oral aprepitant regimen (aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced nausea and vomiting (CINV) in the 120 hours…
- Trial name
- NCT01362530
- Testing
- Aprepitant 125 mg, Aprepitant 80 mg, Aprepitant powder for suspension (PFS)
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Hodgkin's Lymphoma
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
Objectives The primary objective of this study is to: determine the complete and partial response rates and the toxicity profile of bortezomib (VELCADE, formerly PS-341) when administered in combination with DICE chemotherapy…
- Trial name
- NCT00504751
- Testing
- bortezomib, dexamethasone, ifosfamide, mesna, cisplatin, etoposide, rituximab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Weill Medical College of Cornell University
Diffuse Large B Cell Lymphoma
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
The standard of care therapy for DLBCL in the relapsed setting is RICE with the plan for the patient to proceed to transplant. This protocol will add Revlimid to the first 7 days of the RICE therapy and again after transplant as…
- Trial name
- RICER (NCT01241734)
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hackensack Meridian Health
Lymphoma, B-cell Non-Hodgkin's Lymphoma
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
The purpose of this research is to study a treatment program for patients with aggressive lymphoma that has come back after initial or first therapy (called relapsed) or that has not responded to first therapy (called…
- Trial name
- NCT00588094
- Testing
- Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00574496
- Testing
- cyclophosphamide, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
This phase II trial studies the side effects and efficacy of bortezomib with ifosfamide and vinorelbine in children and young adults with Hodgkin's lymphoma that was recurrent or did not respond to previous therapy.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Trial name
- NCT00381940
- Testing
- ifosfamide, bortezomib, vinorelbine tartrate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma
- Trial name
- NCT01055314
- Testing
- Cixutumumab, Cyclophosphamide, Dactinomycin
- Where
- 139 sites in United States, Australia and 2 more
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Chemotherapy-induced Nausea and Vomiting
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen
The goal of this clinical research study is to learn how different doses of fosaprepitant may effect how ifosfamide-based chemotherapy is absorbed by the body.
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Trial name
- NCT01490060
- Testing
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
This phase III trial is studying how well combination chemotherapy works when given before radiation therapy and/or additional chemotherapy in treating young patients with newly diagnosed Hodgkin's lymphoma.
- Conditions
- Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00302003
- Testing
- radiation therapy, doxorubicin hydrochloride, vincristine sulfate
- Where
- United States
- Volunteers
- 287 people
- Sponsor
- Children's Oncology Group
Sarcoma, Soft Tissue
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs…
- Trial name
- NCT00189137
- Testing
- ifosfamide and doxorubicin vs gemcitabine and docetaxel
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Michigan Rogel Cancer Center
Neoplasm Metastasis
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies.
- Trial name
- NCT02677116
- Testing
- Olaratumab, Doxorubicin, Vincristine
- Where
- 21 sites in United States, Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Sarcoma
Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma
RATIONALE: Radioactive drugs, such as samarium Sm 153 lexidronam pentasodium, may carry radiation directly to tumor cells and not harm normal cells.
- Trial name
- NCT00245011
- Testing
- filgrastim, ifosfamide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This phase II/III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- Trial name
- NCT00720109
- Testing
- Asparaginase, Cyclophosphamide, Cytarabine
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Acute Lymphoblastic
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse.
- Trial name
- NCT02393859
- Testing
- Blinatumomab, Dexamethasone, Vincrisitne
- Where
- 103 sites in Argentina, Australia and 22 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Uterine Cancer
Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
The optimal sequence and /or modality for adjuvant therapy in the management of Mixed Mesodermal Tumors (MMT) clearly remains to be established.
- Trial name
- NCT00231842
- Testing
- Ifosfamide, Radiation Therapy, Cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Montefiore Medical Center
Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma
Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors
This phase II trial studies how well chemotherapy followed by radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors that have not spread to other parts of the brain…
- Trial name
- NCT01602666
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Etoposide
- Where
- 167 sites in United States, Australia and 3 more
- Volunteers
- 262 people
- Sponsor
- Children's Oncology Group